Kevin P Killeen, PhD is Chief Scientific Officer at Matrivax Research & Development Corp. Dr. Killeen has extensive training in the fields of molecular biology, microbiology, protein chemistry, immunology, and vaccinology. His undergraduate BS degree is from Stonehill College (biology and chemistry), PhD from University of Rhode Island (microbiology), and post-doctoral fellowship at Harvard Medical School (molecular genetics and protein toxin chemistry). Dr Killeen has 21 years of experience in the field of biotechnology at IDEXX Corp., AVANT-Celldex, and Matrivax. He has published 23 scientific manuscripts, authored four chapters, written several science reviews, is the inventor on six patents, editor of the journal Human Vaccines, and member of the Dean’s Advisory Council at URI. Dr. Killeen was the principal investigator (PI) on vaccine related grants and contracts exceeding $11 million and coordinated greater than $13 million in funding from the Bill & Melinda Gates Foundation. Career highlights include the commercialization of two diagnostic tests, directing six (6) vaccine candidates into Phase 1 and 2 clinical trials, guiding the R&D of CholeraGarde®, an oral, single-dose, cholera vaccine, towards a Phase 3 clinical trial, out- licensing CholeraGarde® to Vaccine Technologies Inc., and identifying/performing scientific due diligence on rotarvirus vaccine candidate 89-12, now Rotarix®, commercialized by GSK.